PARP1 and COVID-19: Notably, recent studies have shown that PARP inhibitors such as CVL218, currently in Phase I clinical trials, have the potential to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication (Ge et al., 2021, 19) and to combat the life-threatening sequelae of coronavirus disease 2019 (COVID-19) through multiple mechanisms (Curtin et al., 2020).